My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

53.86 +0.49 (+0.92%)

Delayed Quote Updated: 10:41 AM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

38 39 Next >

Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time ↗

August 30, 2023

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme

Via Benzinga

3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List ↗

August 28, 2023

Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook.

Via InvestorPlace

Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗

August 23, 2023

Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...

Via Benzinga

How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% ↗

August 23, 2023

Roche provided an update from its study in lung cancer using an anti-TIGIT drug.

Via Investor's Business Daily

Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study ↗

August 23, 2023

Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t

Via Benzinga

Why Novartis Stock Spiked Today ↗

July 18, 2023

A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today.

Via The Motley Fool

Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

August 23, 2023

From Genentech

Via Business Wire

Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition? ↗

August 21, 2023

Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,

Via Benzinga

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

Via Benzinga

Is Regeneron Pharmaceuticals Still a Top Growth Stock? ↗

August 21, 2023

The biotech's focus on innovation could be a boon for shareholders.

Via The Motley Fool

What's Going On With Sonnet BioTherapeutics Stock Today? ↗

August 16, 2023

Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 (IL12-FHAB) in combination with Roche...

Via Benzinga

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales ↗

August 14, 2023

The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.

Via Investor's Business Daily

Is TTOO Stock Really Worth $5? Or Just 5 Cents? ↗

August 09, 2023

TTOO stock has been red hot in recent days, but the story of MULN stock should give speculative investors in T2 Biosystems caution.

Via InvestorPlace

Is AbbVie Still a Good Dividend Stock to Buy? ↗

August 08, 2023

Find out if AbbVie can overcome sinking sales of its top-selling product.

Via The Motley Fool

Why Is Aravive Stock Sinking Today? ↗

August 03, 2023

Aravive Inc (NASDAQ: ARAV) shares plunged after the company's Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary...

Via Benzinga

Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗

July 28, 2023

Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.

Via Benzinga

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗

July 26, 2023

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

Via Benzinga

Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories ↗

July 24, 2023

Wall Street Journal

Via Benzinga

Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗

July 24, 2023

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to

Via Benzinga

New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

July 20, 2023

From Genentech

Via Business Wire

Q2 Earnings Scorecard And Analyst Reports ↗

July 18, 2023

We now have Q2 results from 38 S&P 500 members.

Via Talk Markets

Nvidia Invested $50 million into This AI Drug Discovery Biotech

July 17, 2023

Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from

Via MarketBeat

Topics Artificial Intelligence

2 Nasdaq Stocks That Could Soar This Week ↗

July 16, 2023

BridgeBio Pharma and Roivant Sciences could make big moves this week.

Via The Motley Fool

Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories ↗

July 14, 2023

Benzinga

Via Benzinga

Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover ↗

July 14, 2023

The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed.

Via Investor's Business Daily

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗

July 14, 2023

Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)

Via Benzinga

How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg ↗

July 13, 2023

The companies are rivals in the multiple sclerosis treatment realm with Ocrevus and Briumvi.

Via Investor's Business Daily

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗

July 13, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...

Via Benzinga

Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

July 13, 2023

From Genentech

Via Business Wire

Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk

June 30, 2023

From Genentech

Via Business Wire

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition